| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2014 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 15 | Q2 2024 | 7.8% |
| Morphic Holding Inc | 15 | Q2 2024 | 4.7% |
| UNUM THERAPEUTICS INC | 15 | Q2 2024 | 3.2% |
| INSMED INC | 15 | Q2 2024 | 3.5% |
| MERUS N V | 14 | Q2 2024 | 8.7% |
| VERACYTE INC | 14 | Q2 2024 | 4.9% |
| EVOGENE LTD | 14 | Q2 2024 | 1.6% |
| COMPUGEN LTD | 14 | Q2 2024 | 1.1% |
| CERUS CORP | 13 | Q2 2024 | 3.4% |
| UNITED THERAPEUTICS CORP DEL | 13 | Q4 2023 | 2.2% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Evogene Ltd. | February 14, 2024 | 3,100,000 | 6.1% |
| Mersana Therapeutics, Inc. | February 14, 2024 | 6,420,136 | 5.3% |
| Molecular Templates, Inc. | February 14, 2024 | 354,608 | 6.6% |
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-28 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.